H2 2020 Melanoma Pipeline Review - Featuring AbbVie, Abcuro & Abion Among Other - ResearchAndMarkets.com

DUBLIN--()--The "Melanoma - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 25, 182, 209, 2, 13, 297, 40 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 25, 20, 86 and 12 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Overview
  • Therapeutics Development
  • Therapeutics Assessment
  • Companies Involved in Therapeutics Development
  • Drug Profiles
  • Dormant Projects
  • Discontinued Products
  • Product Development Milestones
  • Appendix

Companies Mentioned

  • 4D Pharma Plc
  • 4SC AG
  • 7 Hills Pharma LLC
  • AbbVie Inc
  • Abcuro Inc
  • Abion Inc
  • Abivax SA
  • ABM Therapeutics Inc
  • AC Bioscience SA
  • Accendatech Co Ltd
  • Accuitis Pharmaceuticals Inc
  • Acepodia Biotech Inc
  • ACF Pharmaceuticals LLC
  • Achilles Therapeutics Ltd
  • Actym Therapeutics Inc
  • Adaptimmune Therapeutics Plc
  • Adare Pharma Solutions
  • ADC Therapeutics SA
  • Adicet Bio Inc
  • Adjuvance Technologies Inc
  • Adlai Nortye Biopharma Co Ltd
  • Advanced BioDesign
  • Advantageous Systems LLC
  • Advenchen Laboratories LLC
  • Aeglea BioTherapeutics Inc
  • Afecta Pharmaceuticals Inc
  • Affichem SA
  • AgenTus Therapeutics Inc
  • Agenus Inc
  • AGV Discovery SAS
  • AIM ImmunoTech Inc
  • AIMM Therapeutics BV
  • AiVita Biomedical Inc
  • Akeso Inc
  • Alkermes Plc
  • Allarity Therapeutics A/S
  • Allergy Therapeutics Plc
  • Alligator Bioscience AB
  • AlphaMab Co Ltd
  • Alphamab Oncology
  • ALS Biopharma LLC
  • Altor Bioscience LLC
  • Amgen Inc
  • Anaveon AG
  • Andes Biotechnologies
  • AnGes Inc
  • Antengene Corp
  • AntiCancer Inc
  • APEIRON Biologics AG
  • Apexian Pharmaceuticals Inc
  • Apexigen Inc
  • Aphios Corp
  • APO-T BV
  • Apogenix AG
  • Apollomics Inc
  • Arcus Biosciences Inc
  • Ardan Pharma
  • Arisaph Pharmaceuticals Inc
  • Asana BioSciences LLC
  • Ascentage Pharma Group International
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Athenex Inc
  • Atreca Inc
  • Among Others

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nt5d33


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900